<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03306264</url>
  </required_header>
  <id_info>
    <org_study_id>ASTX727-02</org_study_id>
    <nct_id>NCT03306264</nct_id>
  </id_info>
  <brief_title>Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML</brief_title>
  <official_title>A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astex Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine.
      Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive
      the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine 20 mg/m^2 Daily×5 in Cycle 2,
      or the converse order. After completion of PK studies during the first 2 treatment cycles,
      subjects will continue to receive treatment with ASTX727 from Cycle 3 onward (in 28-day
      cycles) until disease progression, unacceptable toxicity, or the subject discontinues
      treatment or withdraws from the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 3 study will establish PK equivalence of ASTX727 to IV decitabine in approximately
      118 evaluable subjects. Eligible subjects will receive both study treatments: oral
      investigational drug ASTX727, and IV decitabine, as follows: subjects will be randomly
      assigned 1:1 to receive ASTX727 or IV decitabine in Cycle 1 and then cross over to the other
      therapy in Cycle 2.

      In the ASTX727 cycle, subjects will receive the ASTX727 tablet Daily×5. Serial PK
      measurements (blood draws) will be done on Days 1, 2, and 5, along with pre-dose PK
      assessments on Days 1-5 and an assessment at 3 hours post dose on Day 3. Subjects will be
      required to fast from food for 4 hours on days when receiving ASTX727: at least 2 hours
      before and 2 hours after dosing.

      In the IV decitabine cycle, subjects will receive a 1-hour infusion of IV decitabine 20
      mg/m^2 Daily×5. Serial PK measurements will be done on Days 1 and 5, along with pre-dose and
      1-hour post-infusion assessments on Day 3.

      In Cycles ≥3, subjects will receive the ASTX727 tablet Daily×5 in 28-day cycles. (No PK
      assessments will be done from Cycle 3 onward.)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized, open-label, 2-period, 2-sequence crossover study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total 5-day Area Under the Curve (AUC) exposures of decitabine</measure>
    <time_frame>18 months</time_frame>
    <description>Primary Endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs); the severity (intensity) of AEs will be graded according to CTCAE v4.03.</measure>
    <time_frame>18 months</time_frame>
    <description>Safety assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long Interspersed Nucleotide Elements (LINE)-1 demethylation</measure>
    <time_frame>18 months</time_frame>
    <description>Pharmacodynamics assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>2 months</time_frame>
    <description>Secondary pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration (Tmax)</measure>
    <time_frame>2 months</time_frame>
    <description>Secondary pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant</measure>
    <time_frame>2 months</time_frame>
    <description>Secondary pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total systemic clearance</measure>
    <time_frame>2 months</time_frame>
    <description>Secondary pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent elimination half life</measure>
    <time_frame>2 months</time_frame>
    <description>Secondary pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution</measure>
    <time_frame>2 months</time_frame>
    <description>Secondary pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDS/CMML: Number of participants with complete response (CR), marrow CR, partial response; hematologic improvement based on International Working Group (IWG) 2006 MDS response criteria.</measure>
    <time_frame>18 months</time_frame>
    <description>Efficacy analysis - Clinical response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AML: Number of participants with CR, CR with incomplete platelet recovery (CRp) and CR with incomplete blood count recovery (CRi) based on IWG 2003 AML response criteria</measure>
    <time_frame>18 months</time_frame>
    <description>Efficacy analysis - Clinical response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell (RBC) transfusion independence: defined as no RBC transfusion for 56 consecutive days.</measure>
    <time_frame>18 months</time_frame>
    <description>Efficacy analysis - RBC transfusion independence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet transfusion independence: defined as no platelet transfusion for 8 consecutive weeks.</measure>
    <time_frame>18 months</time_frame>
    <description>Efficacy analysis - Platelet transfusion independence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival in MDS/CMML participants: number of days from date of randomization to date when bone marrow or peripheral blood blasts reach ≥20%, or death.</measure>
    <time_frame>18 months</time_frame>
    <description>Efficacy analysis - Leukemia-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival: number of days from date subject was randomized to date of death.</measure>
    <time_frame>18 months</time_frame>
    <description>Efficacy analysis - Overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>ASTX727</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASTX727 (cedazuridine + decitabine) - Cycle 1 or Cycle 2 (crossover)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV decitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dacogen (decitabine for injection) - Cycle 1 or Cycle 2 (crossover)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASTX727</intervention_name>
    <description>ASTX727 is a tablet for oral administration, containing the fixed-dose combination of 100 mg cedazuridine (a cytidine deaminase inhibitor) and 35 mg decitabine, given by mouth Dailyx5 in 28-day cycles (in Cycle 1 or Cycle 2, then in Cycle 3 and beyond).</description>
    <arm_group_label>ASTX727</arm_group_label>
    <other_name>cedazuridine + decitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacogen</intervention_name>
    <description>Decitabine 20 mg/m^2 one-hour IV infusion Dailyx5 (in one 28-day cycle: either Cycle 1 or Cycle 2).</description>
    <arm_group_label>IV decitabine</arm_group_label>
    <other_name>decitabine for injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to understand and comply with the study procedures, understand the risks involved
             in the study, and provide written informed consent before the first study-specific
             procedure; specifically able to comply with the PK assessment schedule during the
             first 2 treatment cycles.

          2. Men or women ≥18 years who are candidates to receive IV decitabine according to FDA or
             European Medicines Agency (EMA) approved indications:

               1. In North America: Participants with MDS previously treated or untreated with de
                  novo or secondary MDS, including all French-American-British subtypes (refractory
                  anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess
                  blasts, refractory anemia with excess blasts in transformation, and chronic
                  myelomonocytic leukemia [CMML]), and subjects with MDS International Prognostic
                  Scoring System (IPSS) int-1, -2, or high-risk MDS.

               2. In Europe: Participants with de novo or secondary AML, as defined by the World
                  Health Organization (WHO) criteria, who are not candidates for standard induction
                  chemotherapy.

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

          4. Adequate organ function defined as follows:

               1. Hepatic: Total or direct bilirubin ≤2 × upper limit of normal (ULN); aspartate
                  transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine
                  transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ≤2.5 × ULN.

               2. Renal: serum creatinine ≤1.5 × ULN or calculated creatinine clearance or
                  glomerular filtration rate &gt;50 mL/min/1.73 m2 for subjects with creatinine levels
                  above institutional normal.

          5. No major surgery within 30 days of first study treatment.

          6. Life expectancy of at least 3 months.

          7. Women of child-bearing potential must not be pregnant or breastfeeding and must have a
             negative pregnancy test at screening. Women of non-childbearing potential are those
             who have had a hysterectomy or bilateral oophorectomy, or who have completed
             menopause, defined as no menses for at least 1 year AND either age ≥65 years or
             follicle-stimulating hormone levels in the menopausal range.

          8. Subjects and their partners with reproductive potential must agree to use effective
             contraceptive measures during the study and for 3 months after the last dose of study
             treatment. Effective contraception includes methods such as oral contraceptives or
             double-barrier method (eg, use of a condom AND diaphragm, with spermicide).

        Exclusion Criteria:

          1. Prior treatment with more than 1 cycle of azacitidine or decitabine. Prior cytotoxic
             chemotherapy for AML except for hydroxyurea to control high white blood cell (WBC)
             counts.

          2. Hospitalization for more than 2 days for documented febrile neutropenia, pneumonia,
             sepsis, or systemic infection in the 30 days before screening.

          3. Treatment with any investigational drug or therapy within 2 weeks of study treatment,
             or 5 half-lives, whichever is longer, before the first dose of study treatment, or
             ongoing clinically significant adverse events (AEs) from previous treatment.

          4. Cytotoxic chemotherapy or prior azacitidine or decitabine within 4 weeks of first dose
             of study treatment.

          5. Concurrent MDS therapies, including lenalidomide, erythropoietin,
             cyclosporine/tacrolimus, granulocyte-colony stimulating factor (G-CSF),
             granulocyte-macrophage colony-stimulating factor, etc. (Prior treatment with these
             agents is permitted, provided that completion is at least 1 week before the first dose
             of study treatment.)

          6. Poor medical risk because of other conditions such as uncontrolled systemic diseases,
             active uncontrolled infections, or comorbidities that may put the patient at risk of
             not being able to complete at least 2 cycles of treatment.

          7. Known significant mental illness or other condition, such as active alcohol or other
             substance abuse or addiction, that in the opinion of the investigator predisposes the
             subject to high risk of noncompliance with the protocol.

          8. Rapidly progressive or highly proliferative disease (total white blood cell count of
             &gt;15 × 10^9/L) or other criteria that render the subject at high risk of requiring
             intensive cytotoxic chemotherapy within the next 3 months.

          9. Life-threatening illness or severe organ system dysfunction, such as uncontrolled
             congestive heart failure or chronic obstructive pulmonary disease, or other reasons
             including laboratory abnormalities, which, in the investigator's opinion, could
             compromise the subject's safety, interfere with the absorption or metabolism of
             ASTX727, or compromise completion of the study or integrity of the study outcomes.

         10. Prior malignancy, except for adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, prostate cancer or breast cancer under control with
             hormone therapy, or other cancer from which the subject has been disease free for at
             least 2 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold Keer, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Astex Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harold Keer, MD, PhD</last_name>
    <phone>925-719-0741</phone>
    <email>harold.keer@astx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pinnacle Research Group</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Arizona Clinical Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Care Research Group</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Boca Raton Clinical Research</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quincy Medical Group</name>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <zip>62301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Michigan Center of Medical Research</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cancer &amp; Hematology Centers of Western Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monter Cancer Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Penn Allegheny Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology Associates</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9179</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Kadlec Clinic Hematology and Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital Hietzing</name>
      <address>
        <city>Vienna</city>
        <zip>01130</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Geissler, MD</last_name>
      <phone>(43) 699 119 43524</phone>
      <email>Klaus.geissler@wienkav.at</email>
    </contact>
    <investigator>
      <last_name>Klaus Geissler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II (QEII) Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital &amp; Cancer Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center - University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Est-de-l'Ile-de-Montréal - Hôpital Maisonneuve Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Emile Muller</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Ojeda-Uribe, MD</last_name>
      <phone>(33) 89 64 77 55</phone>
      <email>ojeda-uribem@ghrmsa.fr</email>
    </contact>
    <investigator>
      <last_name>Mario Ojeda-Uribe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <state>Baden</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Luebbert</last_name>
      <phone>0761 270 36190</phone>
      <email>michael.luebbert@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Michael Luebbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arpad Illes, MD</last_name>
      <phone>(36) 52 255 196</phone>
      <email>illesarpaddr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Arpad Illes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pecs, 1st Department of Internal Medicine</name>
      <address>
        <city>Pecs</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes Nagy</last_name>
      <phone>(36) 72 536001</phone>
      <email>anagy555@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Agnes Nagy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Bernal del Castillo, MD</last_name>
      <phone>(34) 985108000</phone>
      <phone_ext>37613</phone_ext>
      <email>teresa.bernal@sespa.es</email>
    </contact>
    <investigator>
      <last_name>Teresa Bernal del Castillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital U. Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Colorado Araujo</last_name>
      <phone>(34) 942 203450</phone>
      <email>mercedes.colorado@scsalud.es</email>
    </contact>
    <investigator>
      <last_name>Mercedes Colorado Araujo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Miguel Bergua Burgues, MD</last_name>
      <phone>(34) 927 621546</phone>
      <email>jmberguaburg@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Miguel Bergua Burgues, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Romero Aguilar, MD</last_name>
      <phone>(34) 9580 20000</phone>
      <email>antonio.romero.aguilar.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Antonio Romero Aguilar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Rodriguez Macias, MD</last_name>
      <phone>(34) 915 868394</phone>
      <email>mgabrielarm@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Gabriela Rodriguez Macias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Teresa Cedena, MD</last_name>
      <phone>(34) 917 792324</phone>
      <email>mariateresa.cedena@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Maria Teresa Cedena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Belen Vidriales, MD</last_name>
      <phone>(34) 92 32 91100</phone>
      <phone_ext>55375</phone_ext>
      <email>mbvidri@usal.es</email>
    </contact>
    <investigator>
      <last_name>Maria Belen Vidriales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari I Politècnic La Fe</name>
      <address>
        <city>València</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pau Montesinos Fernandez, MD</last_name>
      <phone>(34) 961 244 000</phone>
      <email>montesinos_pau@gva.es</email>
    </contact>
    <investigator>
      <last_name>Pau Montesinos Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>October 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2017</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS</keyword>
  <keyword>CMML</keyword>
  <keyword>decitabine</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Chronic Myelomonocytic Leukemia</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

